Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 429-440

  Lundy, Amber ^a   Lutfi, Nahla ^a   Beckey, Cherylyn ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ACTION; Calcium channel blocker; Coronary heart disease; Dihydropyridine; Hypertension; Nifedipine

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BUNAZOSIN; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FOSINOPRIL; NIFEDIPINE; PLACEBO; PRAZOSIN; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORTALITY; REVIEW; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG EFFECT; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; HYPERTENSION; NIFEDIPINE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 67449099182     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s3066     Document Type: Review

References (67)

1. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, Texas: American Heart Association; 2008.
2. Mathers C, Boerma T, Fat DM; for WHO staff. The global burden of disease: 2004 update. Accessed Nov 2008. Available from: http://www. who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
4. Sleight P, Yusuf S, Pogue J, Tsuyuki R, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358(9299):2130-2131.
5. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures; A HOPE Substudy. Hypertension. 2000;38:e28-e32.
6. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737.
7. Ellison KE, Gandhi G. Optimizing the use of β-adrenoceptor antagonists in coronary artery disease. Drugs. 2005;65(6):787-797.
8. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117:296-329.
9. Kennedy H. Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT and EMIAT. Am J Cardiol. 1997;80(9):1208-1211.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
11. Mancia G, De Backer G, Dominiczak A, et al. The 2007 Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2007;28:1462-1536.
12. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545-1553.
13. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-1742.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
15. Rosendorff C, Black HR, Cannon CP, et al. AHA Scientific Statement: Treatment of hypertension in the prevention and management of ischemic heart disease.Circulation. 2007;115:2761-2788.
16. Croom KF, Wellington K. Modified-Release Nifedipine: A Review of the use of modified-release formulations in the treatment of hypertension and angina pectoris. Drugs. 2006;66(4):497-528.
17. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in ischaemic heart disease, hypertension, and related cardiovascular disorders. Drugs. 1985;30:182-274.
18. Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS): evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet. 1996;30(1):28-51.
19. Heagerty AM. Nifedipine gastrointestinal therapeutic system - hypertension management to improve cardiovascular outcomes. Int J Clin Pract. 2005;(59)9:1112-1119.
20. Mancini GB. Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis. 2002;45:1-20.
21. Mancini GB, Miller ME, Evans GW; for PREVENT Study Group. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol. 2002;89:1414-1416.
22. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949-2954.
23. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
24. Zanchetti A, Bond MG, Hening M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation. 2002;106:2422-2427.
25. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
26. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
27. Rafflenbeul W. Nifedipine in acute coronary syndromes: Furberg's refrain revisited. Eur Heart J. 1996;17:1147-1152.
28. Tijssen JGP, Hugenholtz PG. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J. 1996;17:1152-1157.
29. Gong L, Zhang W, Zhu Y, et al. Shanghai Trial of Nifedipine in the Elderly (STONE). J Hypertens. 1996;14(10):1237-1245
30. Wu YK. Epidemiology and the community control of hypertension, stroke, and coronary heart disease in China. Chinese Med J. 1979;92:665-670.
31. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan multicenter investigation for cardiovascular diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27(3):181-191.
32. Pristipino C, Beltrame J, Finocchiaro ML, et al; Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation. 2000;101:1102-1108.
33. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res. 2001;24:613-634.
34. Yoshitoshi Y, Kaneko Y, Saruta T. Antihypertensive effect of MK-421 (enalapril maleate) with concomitant thiazide diuretics in patients with essential hypertension: multiclinic pilot, open study. Jpn Pharmacol Ther. 1984;12:3439-3468.
35. Saruta T, Omae T, Iimura O, et al. Efficacy and safety of imidapril (ACE/TA-6366), angiotensin I converting enzyme inhibitor, in monotherapy on essential hypertension multiclinic open study. Rinsho Igaku.1991;7:2485- 2504.
36. Arakawa K, Iimura O, Yoshinaga K, et al. Antihypertensive effect of lisinopril (MK-521) in essential hypertension: result of a multiclinic open trial. Saishin Igaku.1990;45:834-858.
37. Clinical Evaluation of Antihypertensive Drugs Group: Proposed guidelines for the clinical evaluation of antihypertensive drugs. Drug Res. 1979;10:849-864.
38. Shinoda E, Yoshiki Y, Kodama K, et al. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B Side Arm Study). Hyertension. 2005;45:1153-1158.
39. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with long-acting calcium-channel blocker or diuretic in the international nifedipine GITS Study: intervention as a goal in hypertension treatment (INSIGHT). Lancet. 2000;356:366-372.
40. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension. 2001;37:1410-1413.
41. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849-857.
42. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102(13):1503-1510.
43. Ozaki Y, Keane D, Serruys PW. Progression and regression of coronary stenosis in the long-term follow-up of vasospastic angina. Circulation. 1995;92:2446-2456.
44. Dens JA, Desmet WJ, Coussement P, et al. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart. 2003;89:887-892.
45. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2226.
46. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597-603.
47. Fortini A, Cappelletti C, Cecchi L, Laureano R. Fosinopril in the treatment of hypertension: effects on 24 h ambulatory blood pressure and on blood pressure response to exercise. J Hum Hypertens. 1994;8:469-474.
48. Bainbridge AD, Herlihy O, Meredith, PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol. 1993;45:425-430.
49. Kirkendall WM. Comparative assessment of first-line agents for treatment of hypertension. Am J Med. 1988;84(Suppl 3B):32-41.
50. Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists. Am J Cardiol. 1987;59:163B-172B.
51. Chobanian AV. Effects of calcium antagonists and other antihypertensive drugs on atherosclerosis. J Hypertens Suppl. 1987;5(Suppl 4):43-48.
52. Weinstein DB, Heider JG. Protective action of calcium antagonists in atherosclerosis and experimental vascular injury. Am J Hypertens. 1989;2:205-212.
53. Bond MG, Purvis C, Mercuri M. Antiatherogenic properties of calcium antagonists. J Cardiovasc Pharmacol. 1991;17(Suppl 4):87-93.
54. Borhani No, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): A randomized controlled trial. JAMA. 1996;276(10):785-791.
55. Furberg CD, Byington RP, Borhani NO. Design features: multicenter isradipine diuretic atherosclerosis Study (MIDAS). Am J Med. 1989;86(Suppl 4A):37-39.
56. Borhani NO, Bond MG, Sowers JR, et al. The MIDAS: a study of the antiatherogenic properties of isradipine in hypertensive patients. J Cardiovasc Pharmacol. 1991;18(Suppl 3):15-19.
57. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study (STOP-2). Lancet. 1999;354:1751-1756.
58. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. The Lancet. 2005;366 (9489):895-906.
59. Staessen JA, Fagard E, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
60. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129-1133.
61. Dahlof A, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old Patients with hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
62. Savage PJ, Pressel SL, Curb JD; for the SHEP Cooperative Research Group. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1998;158:741-751.
63. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
64. Liu L, Wang G, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
65. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
66. Chobanian AV. Does It Matter How Hypertension Is Controlled? N Engl J Med. 2008;359(23):2485-2487.
67. Hosoda S, Iino T, Yasuda H, et al. Long-term follow-up of medically treated patients with coronary artery disease: incidence of major cardiac events and its risk factors in Japanese with coronary artery disease. Jpn Circ J. 1990;54:231-240.